Astrazeneca (AZN) Intangibles (2009 - 2026)

Astrazeneca's Intangibles history runs 18 years deep, the most recent figure standing at $36.9 billion for Q1 2026.

• In Q1 2026, Intangibles fell 1.71% year-over-year to $36.9 billion; the TTM figure through Mar 2026 stood at $36.9 billion (down 1.71% YoY), while the FY2025 annual figure was $37.8 billion, up 1.8% from the prior year.
• Intangibles was $36.9 billion for Q1 2026 at Astrazeneca, down from $37.8 billion in the prior quarter.
• In the past five years, Intangibles ranged from a high of $41.3 billion in Q1 2022 to a low of $2.7 billion in Q4 2023.
• Historically, Intangibles has averaged $36.5 billion across 5 years, with a median of $38.3 billion in 2023.
• The sharpest annual moves came in 2023 and 2024: Intangibles tumbled 93.11% in 2023, then jumped 1273.37% in 2024.
• A 5-year view of Intangibles shows it stood at $39.3 billion in 2022, then sank by 93.11% to $2.7 billion in 2023, then surged by 1273.37% to $37.2 billion in 2024, then grew by 1.8% to $37.8 billion in 2025, then dropped by 2.48% to $36.9 billion in 2026.
• The last three Intangibles figures came in at $36.9 billion (Q1 2026), $37.8 billion (Q4 2025), and $38.2 billion (Q3 2025), per Business Quant data.